A retrospective study of biochemotherapy for metastatic melanoma: The importance of dose intensity

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 5, 2005, Pages 479-486

  Minor, David R ^a   Madland, Michael T ^c   Kashani Sabet, Mohammed ^b   Denny, Susan R ^a   Harvey, William B ^d  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d California Pacific Medical Center ^*

Author keywords

Biochemotherapy; Dose intensity; Interleukin 2; Melanoma

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TEMOZOLOMIDE; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DOSE RESPONSE; ENDOCARDITIS; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL PATIENT; HUMAN; HYPOTENSION; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MEDIASTINUM METASTASIS; MELANOMA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PERITONEUM METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; CISPLATIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINBLASTINE;

EID: 27744574450     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.479     Document Type: Article

References (24)

1. Legha SS, Ring S, Eton O, et al: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752.
2. O'Day SJ, Gammon G, Boasberg PD, et al: Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 1999;17:2752.
3. Atkins MB, Gollob JA, Sosman JA, et al: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin-2, and IFN-a2b in patients with metastatic melanoma. Clin Cancer Res 2002;8:3075.
4. Allen, IE, Kupeluick B, Kumashvo M, et al: The efficacy on interleukin-2 in the treatment of metastatic melanoma: Systematic review and meta-analysis. Cancer Ther 1998;1:168.
5. Atkins MB, Lee S, Flaherty LE, et al: A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD) IL-2, and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. [abstr.] Proc Amer Soc Clin Oncol 2003;22:708.
6. Keilholz U, Punt CJ, Gore M, et al: Dacarbazine, cisplatin, and IFN-a2b with or without IL-2 in advanced melanoma: Final analysis of EORTC randomized phase III trial 18951. [abstr.] Proc Amer Soc Clin Onc 2003;22:708.
7. DelVecchio M, Bajetta E, Vitali M, et al: Multicenter phase III randomized trial of cisplatin, vindescine, and dacarbazine (CVD) versus CVD plus subcutaneous (s.c.) interleukin-2 (IL-2) and interferon alpha-2b (IFN) in metastatic melanoma patients (pts). [abstr.] Proc Amer Soc Clin Oncol 2003;22:709.
8. Legha SS, Ring S, Eton O, et al: Development and results of biochemotherapy in metastatic melanoma: The University of Texas M. D. Anderson Cancer Center experience. Cancer J Sci Am 1997;3(Suppl 1):S9.
9. Zia MI, Siu LL, Pond GR, et al: Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens. Proc Amer Soc Clin Oncol 2004;22:1966.
10. Shanafelt TD, Loprinzi C, Marks R, et al: Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol 2004;22:1966.
11. Hryniuk WM, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281.
12. Bonadonna G, Valgussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and flurouracil in node-positive breast cancer. New Engl J Med 1995;332:901.
13. Kwak LW, Halpern J, Loshen RA, et al: Prognostic significance of actual dose intensity in diffuse large-cell . lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 1990;8:963.
14. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003;21:1431.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate response to treatment in solid tumors. J Nat Cancer Inst 2000;92;205.
16. O'Day SJ, Boasberg PD, Piro L, et al: Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 2002;8: 2775.
17. Margolin KA. Biochemotherapy for melanoma: Rational therapeutics in the search for weapons of melanoma destruction. Cancer 2004;101:435.
18. Kim KB, Eton O, East MJ, et al. A pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer 2004;101:596.
19. Agarwalla SS, Glaspy J, O'Day SJ, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002;20:125.
20. Legha SS, Ring S, Bedikian A, et al: Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine, and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-a. Ann Onc 1996;7:827.
21. Hu JC, Gold KF, Pashos CL. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol 2003; 21:401.
22. Berkmeyer JD, Siewers AF, Finlayson EVA, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128.
23. Eton O, Legha S, Bedikian Y. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 2002;20:2045.
24. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alpha-2b. J Clin Oncol 1999;17:968.